Cargando…

Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy

As a reference laboratory for measles and rubella surveillance in Lombardy, we evaluated the association between SARS-CoV-2 infection and measles-like syndromes, providing preliminary evidence for undetected early circulation of SARS-CoV-2. Overall, 435 samples from 156 cases were investigated. RNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Amendola, Antonella, Canuti, Marta, Bianchi, Silvia, Kumar, Sudhir, Fappani, Clara, Gori, Maria, Colzani, Daniela, Kosakovsky Pond, Sergei L., Miura, Sayaka, Baggieri, Melissa, Marchi, Antonella, Borghi, Elisa, Zuccotti, Gianvincenzo, Raviglione, Mario C., Magurano, Fabio, Tanzi, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404229/
https://www.ncbi.nlm.nih.gov/pubmed/36029839
http://dx.doi.org/10.1016/j.envres.2022.113979
_version_ 1784773592795316224
author Amendola, Antonella
Canuti, Marta
Bianchi, Silvia
Kumar, Sudhir
Fappani, Clara
Gori, Maria
Colzani, Daniela
Kosakovsky Pond, Sergei L.
Miura, Sayaka
Baggieri, Melissa
Marchi, Antonella
Borghi, Elisa
Zuccotti, Gianvincenzo
Raviglione, Mario C.
Magurano, Fabio
Tanzi, Elisabetta
author_facet Amendola, Antonella
Canuti, Marta
Bianchi, Silvia
Kumar, Sudhir
Fappani, Clara
Gori, Maria
Colzani, Daniela
Kosakovsky Pond, Sergei L.
Miura, Sayaka
Baggieri, Melissa
Marchi, Antonella
Borghi, Elisa
Zuccotti, Gianvincenzo
Raviglione, Mario C.
Magurano, Fabio
Tanzi, Elisabetta
author_sort Amendola, Antonella
collection PubMed
description As a reference laboratory for measles and rubella surveillance in Lombardy, we evaluated the association between SARS-CoV-2 infection and measles-like syndromes, providing preliminary evidence for undetected early circulation of SARS-CoV-2. Overall, 435 samples from 156 cases were investigated. RNA from oropharyngeal swabs (N = 148) and urine (N = 141) was screened with four hemi-nested PCRs and molecular evidence for SARS-CoV-2 infection was found in 13 subjects. Two of the positive patients were from the pandemic period (2/12, 16.7%, March 2020–March 2021) and 11 were from the pre-pandemic period (11/44, 25%, August 2019–February 2020). Sera (N = 146) were tested for anti-SARS-CoV-2 IgG, IgM, and IgA antibodies. Five of the RNA-positive individuals also had detectable anti-SARS-CoV-2 antibodies. No strong evidence of infection was found in samples collected between August 2018 and July 2019 from 100 patients. The earliest sample with evidence of SARS-CoV-2 RNA was from September 12, 2019, and the positive patient was also positive for anti-SARS-CoV-2 antibodies (IgG and IgM). Mutations typical of B.1 strains previously reported to have emerged in January 2020 (C3037T, C14408T, and A23403G), were identified in samples collected as early as October 2019 in Lombardy. One of these mutations (C14408T) was also identified among sequences downloaded from public databases that were obtained by others from samples collected in Brazil in November 2019. We conclude that a SARS-CoV-2 progenitor capable of producing a measles-like syndrome may have emerged in late June-late July 2019 and that viruses with mutations characterizing B.1 strain may have been spreading globally before the first Wuhan outbreak. Our findings should be complemented by high-throughput sequencing to obtain additional sequence information. We highlight the importance of retrospective surveillance studies in understanding the early dynamics of COVID-19 spread and we encourage other groups to perform retrospective investigations to seek confirmatory proofs of early SARS-CoV-2 circulation.
format Online
Article
Text
id pubmed-9404229
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-94042292022-08-25 Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy Amendola, Antonella Canuti, Marta Bianchi, Silvia Kumar, Sudhir Fappani, Clara Gori, Maria Colzani, Daniela Kosakovsky Pond, Sergei L. Miura, Sayaka Baggieri, Melissa Marchi, Antonella Borghi, Elisa Zuccotti, Gianvincenzo Raviglione, Mario C. Magurano, Fabio Tanzi, Elisabetta Environ Res Article As a reference laboratory for measles and rubella surveillance in Lombardy, we evaluated the association between SARS-CoV-2 infection and measles-like syndromes, providing preliminary evidence for undetected early circulation of SARS-CoV-2. Overall, 435 samples from 156 cases were investigated. RNA from oropharyngeal swabs (N = 148) and urine (N = 141) was screened with four hemi-nested PCRs and molecular evidence for SARS-CoV-2 infection was found in 13 subjects. Two of the positive patients were from the pandemic period (2/12, 16.7%, March 2020–March 2021) and 11 were from the pre-pandemic period (11/44, 25%, August 2019–February 2020). Sera (N = 146) were tested for anti-SARS-CoV-2 IgG, IgM, and IgA antibodies. Five of the RNA-positive individuals also had detectable anti-SARS-CoV-2 antibodies. No strong evidence of infection was found in samples collected between August 2018 and July 2019 from 100 patients. The earliest sample with evidence of SARS-CoV-2 RNA was from September 12, 2019, and the positive patient was also positive for anti-SARS-CoV-2 antibodies (IgG and IgM). Mutations typical of B.1 strains previously reported to have emerged in January 2020 (C3037T, C14408T, and A23403G), were identified in samples collected as early as October 2019 in Lombardy. One of these mutations (C14408T) was also identified among sequences downloaded from public databases that were obtained by others from samples collected in Brazil in November 2019. We conclude that a SARS-CoV-2 progenitor capable of producing a measles-like syndrome may have emerged in late June-late July 2019 and that viruses with mutations characterizing B.1 strain may have been spreading globally before the first Wuhan outbreak. Our findings should be complemented by high-throughput sequencing to obtain additional sequence information. We highlight the importance of retrospective surveillance studies in understanding the early dynamics of COVID-19 spread and we encourage other groups to perform retrospective investigations to seek confirmatory proofs of early SARS-CoV-2 circulation. The Authors. Published by Elsevier Inc. 2022-12 2022-08-25 /pmc/articles/PMC9404229/ /pubmed/36029839 http://dx.doi.org/10.1016/j.envres.2022.113979 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Amendola, Antonella
Canuti, Marta
Bianchi, Silvia
Kumar, Sudhir
Fappani, Clara
Gori, Maria
Colzani, Daniela
Kosakovsky Pond, Sergei L.
Miura, Sayaka
Baggieri, Melissa
Marchi, Antonella
Borghi, Elisa
Zuccotti, Gianvincenzo
Raviglione, Mario C.
Magurano, Fabio
Tanzi, Elisabetta
Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy
title Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy
title_full Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy
title_fullStr Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy
title_full_unstemmed Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy
title_short Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy
title_sort molecular evidence for sars-cov-2 in samples collected from patients with morbilliform eruptions since late 2019 in lombardy, northern italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404229/
https://www.ncbi.nlm.nih.gov/pubmed/36029839
http://dx.doi.org/10.1016/j.envres.2022.113979
work_keys_str_mv AT amendolaantonella molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT canutimarta molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT bianchisilvia molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT kumarsudhir molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT fappaniclara molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT gorimaria molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT colzanidaniela molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT kosakovskypondsergeil molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT miurasayaka molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT baggierimelissa molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT marchiantonella molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT borghielisa molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT zuccottigianvincenzo molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT raviglionemarioc molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT maguranofabio molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly
AT tanzielisabetta molecularevidenceforsarscov2insamplescollectedfrompatientswithmorbilliformeruptionssincelate2019inlombardynorthernitaly